Catalent Inc Stock Price, News & Analysis

Exelixis (Nasdaq: EXEL) has entered a new licensing agreement with Catalent (NYSE: CTLT) for three oncology programs aimed at developing antibody-drug conjugates (ADCs) for various solid tumors. Exelixis will pay $30 million upfront for rights to the biologics programs and will fund the development until candidate selection. This collaboration enhances Exelixis’ biologics pipeline, targeting cancers including bladder, breast, and ovarian. Catalent's SMARTag technology will support the development, potentially improving treatment options for cancer patients.

Catalent reported Q1'23 net revenue of $1.02 billion, unchanged from last year but up 4% in constant currency. Organic net revenue dipped 1%. Adjusted EBITDA fell 26% to $187 million. Results were negatively impacted by $54 million due to contract timing but are expected to be recognized in Q2'23. The acquisition of Metrics Contract Services for $475 million was finalized in October 2022. Updated guidance for FY'23 projects net revenue between $4,625 million and $4,875 million with Adjusted EBITDA of $1,220 million to $1,300 million.

Catalent, Inc. (NYSE: CTLT) will announce its financial results for Q1 FY2023 on November 1, 2022, before market open. The results cover the period ending September 30, 2022. Following the release, a management webcast is scheduled for 8:15 a.m. ET on the same day to discuss the results. A supplemental presentation will be available on the company's website, and the webcast replay will last for 90 days. Catalent, a leader in drug development and manufacturing, generated nearly $5 billion in revenue in FY2022.

Catalent, Inc. (NYSE: CTLT) is set to participate in two investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:45 a.m. ET, and the Baird’s 2022 Global Healthcare Conference on September 14 at 10:50 a.m. ET. A live webcast of these presentations will be available on their investor website, with replays following the events. Catalent is a global leader in optimizing product development and supply for pharma, biotech, and consumer health, generating nearly $5 billion in revenue in FY2022.

Catalent, Inc. (CTLT) reported a robust Q4'22 net revenue of $1.31 billion, a 10% increase year-over-year, with a 15% growth in constant currency. For FY'22, total net revenue reached $4.83 billion, up 21% as reported. Q4'22 net earnings soared to $188 million, translating to $1.04 per share. Adjusted EBITDA for Q4'22 was $384 million, marking a 10% increase, while FY'22 Adjusted EBITDA hit $1.29 billion, a 26% rise. FY'23 guidance estimates net revenue between $4,975 million and $5,225 million.

Catalent has announced its acquisition of Metrics Contract Services for $475 million from Mayne Pharma, aiming to enhance its capabilities in oral solid formulation development and manufacturing. The acquisition includes Metrics' 333,000 square-foot facility in Greenville, North Carolina, featuring significant investment in upgrades and the capacity to produce over one billion oral solid dose units annually. This strategic move will allow Catalent to meet growing customer demands in the biopharma sector.

Catalent (NYSE:CTLT) will release its financial results for the fourth quarter of fiscal year 2022, ending June 30, 2022, on August 29, 2022, before market opening. A webcast discussing these results will follow at 8:15 AM ET on the same day. Catalent is recognized as a leader in advanced delivery technologies and clinical supply solutions for pharmaceuticals and consumer health products, generating approximately $4 billion in revenue during the 2021 fiscal year and supporting over 1,000 partner programs annually.

Catalent, Inc. (NYSE: CTLT) has restructured its operations from four reporting segments to two as of July 1. The new segments focus on Biologics and Pharma and Consumer Health, with the latter consolidating multiple previous segments to enhance service integration. This change aims to better align with customer needs and industry trends, as stated by CEO Alessandro Maselli. Leadership changes include new roles for Jonathan Arnold and Steven Fasman, while Karen Flynn has announced her retirement.